H. Lundbeck A/S (LUN.CO)


Copenhagen - Copenhagen Delayed Price. Currency in DKK
230.10-41.60 (-15.31%)
At close: 10:59 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open237.50
Prev Close271.70
Bid230.00 x
Ask230.20 x
Day's Range225.00 - 237.90
52wk Range177.20 - 290.50
1y Target EstN/A
Market Cap45.47B
P/E Ratio (ttm)-35.14
BetaN/A
Volume2,474,305
Avg Vol (3m)294,952
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Bloomberg2 days ago

    Lundbeck Falls After Alzheimer’s Drug Fails in Late-Stage Study

    H. Lundbeck A/S dropped the most in almost four years after its experimental Alzheimer’s drug failed to meet targets in a final-stage patient trial.

  • Axovant shares slammed after rival Alzheimer's treatment data disappoints
    CNBC3 days ago

    Axovant shares slammed after rival Alzheimer's treatment data disappoints

    The company's lead Alzheimer's candidate is similar to the product that disappointed in a competitor's clinical trials.

  • Reuters3 days ago

    Lundbeck says Alzheimer's drug fails in late-stage study

    Danish drugmaker H Lundbeck A/S's highly anticipated experimental Alzheimer's drug failed in a late-stage study, underscoring the challenges faced by drugmakers to tackle the debilitating memory-robbing disease. The Copenhagen-based company said on Thursday both doses of the drug, idalopirdine, showed a "weak efficacy profile" and failed to reduce cognitive decline measured on a scale called ADAS-cog in the study named Starshine. Idalopirdine, which is being developed with Japan's Otsuka Pharmaceutical Co Ltd, is being tested in patients with mild to moderate Alzheimer's disease.